- Home
- BVS
BVS
Bioventus Inc.
as 01-17-2025 4:00pm EST
Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | DURHAM |
| Market Cap: | 698.1M | IPO Year: | 2021 |
| Target Price: | $15.00 | AVG Volume (30 days): | 345.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.90 - $14.38 | Next Earning Date: | 03-11-2025 |
| Revenue: | $555,061,000 | Revenue Growth: | 10.40% |
| Revenue Growth (this year): | 11.37% | Revenue Growth (next year): | 1.04% |
Stock Insider Trading Activity of Bioventus Inc. (BVS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Claypoole Robert E | BVS | President and CEO | Jan 13 '25 | Sell | $9.10 | 28,786 | $261,952.60 | 64,964 | |
| Singleton Mark Leonard | BVS | SVP & CFO | Dec 23 '24 | Sell | $10.53 | 10,733 | $113,018.49 | 105,162 | |
| D'Adamio Anthony | BVS | SVP & General Counsel | Dec 23 '24 | Sell | $10.53 | 5,848 | $61,579.44 | 109,578 | |
| CHURCH KATRINA J | BVS | SVP & Chief Compliance Officer | Dec 23 '24 | Sell | $10.53 | 2,535 | $26,693.55 | 47,264 |
Latest Bioventus Inc. News
BVS Breaking Stock News: Dive into BVS Ticker-Specific Updates for Smart Investing
GlobeNewswire
12 days ago
Bioventus to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Zacks
16 days ago
BVS Stock Gains Post Divestiture of Advanced Rehabilitation Business
TipRanks
16 days ago
Bioventus completes divestiture of its Advanced Rehabilitation business
MT Newswires
17 days ago
Bioventus Sells Advanced Rehabilitation Business to Accelmed Partners
GlobeNewswire
17 days ago
Bioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed Partners
Zacks
a month ago
Is Bioventus (BVS) Outperforming Other Medical Stocks This Year?
MT Newswires
a month ago
JPMorgan Upgrades Bioventus to Neutral From Underweight, Adjusts Price Target to $13 From $12
Zacks
a month ago
Wall Street Analysts Think Bioventus (BVS) Could Surge 26.03%: Read This Before Placing a Bet
Compare BVS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BVS Bioventus Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.